AUDENTES THERAPEUTICS, INC.Merger Agreement • December 16th, 2019 • Astellas Pharma Inc. • Biological products, (no disgnostic substances)
The information contained in this Summary Term Sheet is a summary only and is not meant to be a substitute for the more detailed description and information contained in the remainder of this Offer to Purchase (as it may be amended, supplemented or otherwise modified from time to time, the “Offer to Purchase”), the Letter of Transmittal (as it may be amended, supplemented or otherwise modified from time to time, the “Letter of Transmittal”) and other related materials. You are urged to read carefully this Offer to Purchase, the Letter of Transmittal and other related materials in their entirety. This Summary Term Sheet includes cross-references to other sections of this Offer to Purchase where you will find more complete descriptions of the topics mentioned below. The information concerning Audentes contained in this Summary Term Sheet and elsewhere in this Offer to Purchase has been provided to Astellas and Purchaser by Audentes or has been taken from, or is based upon, publicly avail
